AstraZeneca Imfinzi plus chemotherapy approved in China for locally advanced or metastatic biliary tract cancer Ruchika Sharma19 Nov 2023 6:15 AM GMTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
Merck bags USFDA nod for Keytruda plus gemcitabine, cisplatin to treat Biliary Tract Cancer Ruchika Sharma2 Nov 2023 9:00 AM GMTKEYTRUDA is an anti-programmed death receptor-1 (PD-1) therapy that works by increasing the ability of the body's immune system to help detect and...
USFDA accepts application for Merck KEYTRUDA plus chemotherapy as treatment for Biliary Tract Cancer Ruchika Sharma9 Jun 2023 12:00 PM GMTRahway: Merck, known as MSD outside of the United States and Canada, has announced the U.S. Food and Drug Administration (FDA) has accepted for review...
AstraZeneca India gets CDSCO nod for Durvalumab to treat biliary tract cancer Ruchika Sharma17 Feb 2023 6:30 AM GMTNew Delhi: Science-led biopharmaceutical company, AstraZeneca India, has announced additional indication approval from Central Drugs...
Medical Bulletin 23/January/2023 Isra Zaman23 Jan 2023 9:00 AM GMTHere are the top medical news for the day:Modified bacteria to tackle drug-resistant lung infectionsResearchers have designed the first ‘living...
Nab-paclitaxel does not extend survival in biliary tract cancer; though has benefits for some Isra Zaman23 Jan 2023 3:45 AM GMTAdding nab-paclitaxel to a standard treatment of gemcitabine plus cisplatin does not significantly extend median overall survival (OS) time for...
AstraZeneca gets Japanese approval for Imfinzi, Imjudo to treat 3 types of cancer Ruchika Sharma28 Dec 2022 6:00 AM GMTImfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80...
AstraZeneca gets USFDA nod for Imfinzi plus chemotherapy to treat advanced biliary tract cancer Ruchika Sharma5 Sep 2022 8:00 AM GMTBiliary tract cancer is a group of rare and aggressive cancers that occur in the bile ducts and gallbladder.
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: study Dr. Shravani Dali7 July 2022 2:30 PM GMTDurvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer, according to a recent study published in the NEJM Evidence Patients...
Gallium 68-labeled FAPI-PET promising for biliary tract cancer detection: Study Medha Baranwal25 May 2022 12:30 AM GMTChina: Gallium 68-labeled fibroblast-activation protein inhibitor (FAPI)-PET imaging is superior to current methods for more accurate staging of...
Durvalumab Significantly Improves Survival for Patients With Biliary Tract Cancer Compared to Chemotherapy Alone Dr. Kamal Kant Kohli29 Jan 2022 3:30 AM GMTBiliary tract cancer is classified as a rare disease comprised primarily of bile duct and gallbladder cancers.Results from a randomized international...
Long term use of PPIs Increase the Risk of Biliary Tract Cancer: Study MD Bureau1 Jun 2021 3:15 AM GMTBiliary tract cancer is a heterogeneous group of aggressive malignant disorders constituting ~3% of all gastrointestinal malignancies. In a recent...
